Neovacs S.A. (EPA:ALNEV)
France · Delayed Price · Currency is EUR 0.0004
0.00 (0.00%)
Jun 2, 2026, 5:29 PM CET
Neovacs Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 0.13 | 0.29 | 0.53 | 0 | 0.02 | 0.03 |
Other Revenue | 0.07 | 0.14 | - | - | - | - |
| 0.2 | 0.43 | 0.53 | 0 | 0.02 | 0.03 | |
Revenue Growth (YoY) | -75.80% | -18.65% | 47868.71% | -95.07% | -24.32% | -68.70% |
Cost of Revenue | 3.11 | 3.2 | 4 | 3.4 | 4.56 | 1.72 |
Gross Profit | -2.91 | -2.77 | -3.47 | -3.4 | -4.54 | -1.69 |
Selling, General & Admin | 2.49 | 3.03 | 3.12 | 2.71 | 2.96 | 1.65 |
Other Operating Expenses | 0.13 | 0.63 | 0.15 | 0.18 | 0.23 | 0.1 |
Operating Expenses | 2.8 | 3.85 | 3.44 | 3.04 | 3.29 | 1.8 |
Operating Income | -5.71 | -6.62 | -6.91 | -6.44 | -7.83 | -3.49 |
Interest Expense | -0.66 | - | - | - | -0 | -0 |
Interest & Investment Income | 0.81 | 1.16 | 4.19 | 4.22 | 0.19 | 0 |
Currency Exchange Gain (Loss) | - | - | -0.14 | -0.07 | 0 | - |
Other Non Operating Income (Expenses) | -22.15 | -28.02 | -6.08 | -0.9 | -2.06 | -2.13 |
EBT Excluding Unusual Items | -27.7 | -33.49 | -8.94 | -3.19 | -9.7 | -5.61 |
Gain (Loss) on Sale of Investments | -1.25 | -1.25 | -0.33 | -0.08 | -0.18 | - |
Asset Writedown | -0.01 | -0.01 | - | - | -0 | - |
Other Unusual Items | 23.5 | 0.79 | -0.35 | -1.08 | -2.6 | -1.07 |
Pretax Income | -5.46 | -33.95 | -9.62 | -4.35 | -12.48 | -6.68 |
Income Tax Expense | -1.1 | -1.03 | -0.88 | -0.8 | -0.64 | -0.54 |
Net Income | -4.36 | -32.91 | -8.74 | -3.55 | -11.84 | -6.14 |
Net Income to Common | -4.36 | -32.91 | -8.74 | -3.55 | -11.84 | -6.14 |
Shares Outstanding (Basic) | 0 | - | - | 241 | 2 | 674 |
Shares Outstanding (Diluted) | 0 | - | - | 241 | 2 | 674 |
Shares Change (YoY) | - | - | - | 12025.88% | -99.70% | 327.36% |
EPS (Basic) | -9.14 | - | - | -0.01 | -5.95 | -0.01 |
EPS (Diluted) | -9.14 | - | - | -0.01 | -5.95 | -0.01 |
Free Cash Flow | -3.11 | -3.68 | -2.12 | -4.6 | -10.26 | -5.86 |
Free Cash Flow Per Share | -6.53 | - | - | -0.02 | -5.15 | -0.01 |
Operating Margin | -2866.37% | -1525.96% | -1294.97% | -579583.27% | -34725.65% | -11723.46% |
Profit Margin | -2186.98% | -7585.07% | -1639.15% | -319109.98% | -52512.21% | -20624.03% |
Free Cash Flow Margin | -1561.34% | -848.26% | -396.80% | -413782.37% | -45498.69% | -19665.26% |
EBITDA | -5.52 | -6.43 | -6.74 | -6.29 | -7.73 | -3.44 |
D&A For EBITDA | 0.19 | 0.19 | 0.16 | 0.15 | 0.1 | 0.06 |
EBIT | -5.71 | -6.62 | -6.91 | -6.44 | -7.83 | -3.49 |
Revenue as Reported | 0.2 | 0.51 | 0.54 | 0.01 | - | 0.03 |